
Sanofi backs Lifordi with investment for arthritis trial
Sanofi Ventures has invested in biotechnology company Lifordi Therapeutics, bringing Lifordi’s total financing round up to $112 million. The funding is set to be used to support an ongoing Phase I study in Rheumatoid Arthritis (RA) by evaluating LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. It also provides for… Read More














